By Fineline Cube 
Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant currency, driven by sharp drops in COVID‑19 product sales. Excluding Comirnaty and Paxlovid, the non‑COVID portfolio grew 6% for the year and 9% in Q4. The company reaffirmed 2026 guidance of USD 59.5–62.5 billion despite projected generic headwinds.
Financial Performance Summary
| Metric | Q4 2025 | Full‑Year 2025 | YOY Growth (Operational) |
|---|---|---|---|
| Total Revenue | USD 17.6 B | USD 62.6 B | -2% |
| Pharmaceutical Sales | USD 14.84 B | — | -3% (Q4), -2% (FY) |
| Non‑COVID Portfolio | — | — | +9% (Q4), +6% (FY) |
| 2026 Revenue Guidance | — | USD 59.5–62.5 B | — |
| EPS Guidance (2026) | — | USD 2.80–3.00 | — |
Key Product Sales Performance
| Product | 2025 Sales | YOY Growth | Strategic Role |
|---|---|---|---|
| Abrysvo (RSV vaccine) | USD 481 M | +143% | Vaccine portfolio growth |
| Eliquis (apixaban) | USD 2.02 B | +8% | Cardiovascular stable |
| Prevnar family | USD 1.7 B | +8% | Established vaccine |
| Vyndaqel (tafamidis) | USD 1.7 B | +7% | Rare disease expansion |
| Padcev (enfortumab vedotin) | USD 508 M | +15% | Oncology ADC growth |
| Comirnaty | USD 2.27 B | -35% | COVID vaccine decline |
| Paxlovid | USD 218 M | -70% | COVID therapeutic slump |
COVID Portfolio Impact & 2026 Outlook
- COVID Revenue Decline: Comirnaty and Paxlovid combined contributed ~USD 2.5 B : in 2025 vs. ~USD 8 B : in 2024
- 2026 COVID Forecast: CFO David Denton expects COVID products to generate ~USD 5 billion in 2026
- Generic Headwinds: USD 1.5 billion revenue compression expected from anticipated generic entry in 2026
Pipeline & Strategic Updates
- 2025 Pivotal Starts: 11 pivotal studies initiated
- 2026 Pipeline: ~20 pivotal starts expected, including 10 for ultra‑long‑acting obesity assets from Metsera and 4 for PF‑08634404 (PD‑1 x VEGF bispecific) in‑licensed from 3SBio
- Obesity Data: Phase IIb Vesper‑3 trial for PF‑08653944 showed 10–12.3% placebo‑adjusted weight loss with monthly dosing
- ACCELERATE Partnerships: Ongoing oncology collaborations and YaoPharma peptide therapeutic development
Forward‑Looking Statements
This brief contains forward‑looking statements regarding revenue projections, pipeline development, and commercial prospects for Pfizer’s portfolio. Actual results may differ due to competitive dynamics, regulatory approvals, and market conditions.-Fineline Info & Tech